3-羧基哒嗪 | 2164-61-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-羧基哒嗪
• 中文别名: 哒嗪-3-羧酸
• 英文名称: pyridazine-3-carboxylic acid
• 英文别名: 3-pyridazinecarboxylic acid；Pyridazin-3-carbonsaeure
• CAS: 2164-61-6
• 化学式: C₅H₄N₂O₂
• mdl: MFCD01646333
• 分子量: 124.099
• InChiKey: RUUOPSRRIKJHNH-UHFFFAOYSA-N

物化性质

• 熔点：
  200-209 °C
• 沸点：
  404.2±18.0 °C(Predicted)
• 密度：
  1.403±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933990090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

SDS

Name:	3-Pyridazinecarboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	2164-61-6

Section 1 - Chemical Product MSDS Name:3-Pyridazinecarboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2164-61-6	3-Pyridazinecarboxylic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2164-61-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 103.8 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H4N2O2
Molecular Weight: 124.1

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2164-61-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Pyridazinecarboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 2164-61-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2164-61-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2164-61-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-羧基哒嗪 生成 哒嗪
  参考文献：
  名称：

  Gabriel; Colman, Chemische Berichte, 1899, vol. 32, p. 398

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲基哒嗪 在 吡啶 、 selenium(IV) oxide 、 水 作用下， 反应 21.0h， 生成 3-羧基哒嗪
  参考文献：
  名称：

  基于非铁（II）的传感器：晶体学洞察到一系列由客体引起的定势变换的循环

  摘要：

  能够通过一组易于监视的输出来在室温下感测挥发性客体的材料对于发展为小型挥发性有机物和有毒气体的化学传感器具有极大的吸引力。本文中的双核铁（II）配合物，的[Fe II 2（大号）2（CH 3 CN）4 ]（BF 4）4 ⋅2CH 3 CN（1）[大号= 4-（4-甲基苯基）-3- （3-吡啶哒嗪基）-5-吡啶基-4H-1,2,4-三唑]被证明在暴露于不同客体蒸气下会经历可逆的单晶至单晶（SCSC）转化：1（MeCN ）⇌ 2（乙醇）→ 3（H 2 O）⇌ 1（MeCN中）。当1和2保持双金属状态时，SCSC至3涉及转化为一维聚合物链（由于L桥接模式的改变），该链显着地可以进行SCSC解聚，从而重整双金属1。此外，对两个有序瞬态形式1TF3和2TF3的SC‐XRD研究证实，随着旧来宾的离开，新来宾扩散到无孔晶格中，从而发生了来宾交换。这些可逆的SCSC事件还引起颜色和磁响应。确实，深红色1具有自旋交叉活性（T

  DOI：

  10.1002/anie.201608813

文献信息

• 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途
  申请人：中国医学科学院药物研究所

  公开号：CN112279835B

  公开（公告）日：2022-07-22

  本发明涉及一类含芳环或芳杂环并咪唑结构的化合物或其药学上可接受盐，其制备方法，含有该类化合物的药物组合物以及该类化合物的医药用途。本发明化合物具有特异性激动STING蛋白的作用，能够用于制备治疗恶性肿瘤、病毒感染等与STING蛋白功能相关的疾病的药物。
• 1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists
  作者：Fabrizio Micheli、Andrea Bernardelli、Federica Bianchi、Simone Braggio、Laura Castelletti、Palmina Cavallini、Paolo Cavanni、Susanna Cremonesi、Michele Dal Cin、Aldo Feriani、Beatrice Oliosi、Teresa Semeraro、Luca Tarsi、Silvia Tomelleri、Andrea Wong、Filippo Visentini、Laura Zonzini、Christian Heidbreder

  DOI：10.1016/j.bmc.2016.02.031

  日期：2016.4

  high affinity and selectivity at the DA D3 receptor is reported here. Compounds endowed with high selectivity over the hERG channel were identified and their pharmacokinetic properties thoroughly analyzed. A few derivatives with appropriate developability characteristics were selected for further studies and progression along the screening cascade. In particular, derivative 60a, (DA D3 pKi = 8.4, DA D2

  本文报道了一系列新的1,2,4-三唑基八氢吡咯并[2,3- b ]吡咯在DA D3受体上表现出高亲和力和选择性。鉴定了在hERG通道上具有高选择性的化合物，并对其药代动力学特性进行了全面分析。选择了一些具有适当可显影性的衍生物，以进一步研究并沿着筛选级联进行。特别地，衍生物60a（DA D3 p K i  ＝ 8.4，DA D2 p K i  ＝ 6.0和hERG fp K i  ＝ 5.2）显示出平衡的分布，并且围绕该分子进行进一步的改进。
• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists
  作者：Qiumu Xi、Mingjin Wang、Wenqiang Jia、Mingjian Yang、Jinping Hu、Jing Jin、Xiaoguang Chen、Dali Yin、Xiaojian Wang

  DOI：10.1021/acs.jmedchem.9b01567

  日期：2020.1.9

  Stimulator of interferon genes (STING) is an endoplasmic reticulum-localized adaptor protein (STING receptor) that has been shown to be activated by binding to natural cyclic dinucleotide (CDN) ligands and plays a vital role in innate immune sensing of exogenous or endogenous DNA, which then induces type I interferons and other cytokines. In this paper, we described a series of amidobenzimidazole STING

  干扰素基因刺激物（STING）是一种内质网定位的衔接蛋白（STING受体），已被证明可通过与天然环二核苷酸（CDN）配体结合而被激活，并且在外源或内源DNA的固有免疫传感中起着至关重要的作用然后诱导I型干扰素和其他细胞因子。在本文中，我们描述了一系列对STING受体具有高效力的酰胺基苯并咪唑STING激动剂，并提出了相关的构效关系（SAR）。通过STING竞争结合测定法测量化合物16g，24b和24e的相对效力。对STING信号通路影响的更彻底研究表明，三种化合物16g，24b和24e显着增加了IFN-β，CXCL10和IL-6的蛋白质水平和mRNA水平，以及作为代表化合物的24b有效地触发了人类外周血单核细胞（hPBMC）和WT THP-1细胞中STING，TBK1和IRF3的磷酸化。另外，化合物24b在具有确定的同基因结肠肿瘤的小鼠中通过静脉内给药显示出令人印象深刻的抗肿瘤功效。此外，
• 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists
  作者：Fabrizio Micheli、Alessia Bacchi、Simone Braggio、Laura Castelletti、Palmina Cavallini、Paolo Cavanni、Susanna Cremonesi、Michele Dal Cin、Aldo Feriani、Sylvie Gehanne、Mahmud Kajbaf、Luciano Marchió、Selena Nola、Beatrice Oliosi、Annalisa Pellacani、Elisabetta Perdonà、Anna Sava、Teresa Semeraro、Luca Tarsi、Silvia Tomelleri、Andrea Wong、Filippo Visentini、Laura Zonzini、Christian Heidbreder

  DOI：10.1021/acs.jmedchem.6b00972

  日期：2016.9.22

  A novel series of 1,2,4-triazolyl 5-azaspiro[2.4]heptanes with high affinity and selectivity at the dopamine (DA) D3 receptor (D3R) is described. Some of these compounds also have high selectivity over the hERG channel and were characterized with respect to their pharmacokinetic properties both in vitro and in vivo during lead identification and early lead optimization phases. A few derivatives with

  描述了一个新的1,2,4-三唑基5-氮杂螺[2.4]庚烷系列，对多巴胺（DA）D3受体（D3R）具有高亲和力和选择性。这些化合物中的一些在hERG通道上也具有很高的选择性，并且在铅鉴定和早期铅优化阶段的体内和体外药代动力学特性方面进行了表征。选择了一些具有总体良好的可开发性特征的衍生物用于进一步的后期铅优化研究。